FY2022 Q3 Financial and R&D Update

HR+ Status of Clinical Studies in Breast Cancer Neoadjuvant/ Adjuvant 1L 2L 3L HER2+ DESTINY DESTINY -Breast11 -Breast05 DESTINY -Breast09 HER2 low HER2 IHC >0<1+ HER2 IHC O TNBC Pivotal studies only, not exhaustive Daiichi-Sankyo DESTINY -Breast06 DESTINY-Breast02/03 (HER2+) ENHERTUⓇ DESTINY-Breast04 (HER2-low) DESTINY-Breast06 FY2023 H1: TLR anticipated (Post ET, chemo naïve) TROPION-Breast01 Dato-DXd TROPION -Breast03 TROPION -Breast02 DESTINY -Breast04 (HER2-low) In HR+ BC, the line of therapy indicates post-ET setting. TROPION-Breast03 Dec 2022: Study started chemo: chemotherapy, ET: endocrine therapy, HR: hormone receptor, IHC: immunohistochemistry, TLR: top line results, TNBC: triple-negative breast cancer 26

View entire presentation